Core Insights - Lantheus Holdings, Inc. announced the presentation of new data on florbetaben F18 at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference, scheduled for December 1-4 in San Diego, CA [1] Group 1: Presentation Details - The poster presentation will take place on December 3, 2025, from 7:15 AM to 5:30 PM PT, under session number 06 titled "Clinical Trials: Imaging" [2] - The poster is titled "Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab" and is numbered P184, presented by Marianne Chapleau from Life Molecular Imaging [2] Group 2: Product Information - Neuraceq (florbetaben F 18 injection) is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment [2] - The overall safety profile of Neuraceq is based on data from 1,090 administrations to 872 subjects, with common adverse reactions including injection site pain (3.4%), erythema (1.7%), and irritation (1.1%) [6] Group 3: Company Overview - Lantheus is a leading radiopharmaceutical-focused company that has been providing solutions for nearly 70 years, enabling the evaluation of Alzheimer's disease and other cognitive decline causes [7][8] - The company is headquartered in Massachusetts and has offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [8]